Company / Accounts Receivable
Catalyst Pharmaceuticals Partners, Inc. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$126.5M
FY2025
5-year range
$6.6M / $126.5M
FY2021-FY2025
Trend
+93.2%
vs FY2024
Sector context
#45 of 112
Health Care
What the data says
At $126M, Catalyst Pharmaceuticals Partners, Inc.'s accounts receivable ranks #45 of 112 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $6M in FY2020 to $126M in FY2025.
Based on SEC 10-K filings.
$126M in FY2025 with a 5-year CAGR of +84.1%.
Improved from $54M to $126M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +129.7%
- 5-Year CAGR
- +84.1%
- 10-Year CAGR
- -
Sector benchmark
#45 of 112 in Health CareTop 40% of 112This company $126.5M Sector average $1.1B
▼
-88.9% below sector average
Key checks
Key Insights
- Catalyst Pharmaceuticals Partners, Inc.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +84.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 93.2% year-over-year.
- Ranks #45 out of 112 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $126.5M | +93.2% |
| FY2024 | $65.5M | +22.4% |
| FY2023 | $53.5M | +412.6% |
| FY2022 | $10.4M | +57.7% |
| FY2021 | $6.6M | +10.6% |
| FY2020 | $6.0M | -43.2% |
| FY2019 | $10.5M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026